Replies to post #28499 on RespireRx Pharmaceuticals Inc (RSPI)

[jerrydylan]

Don't forget the .34 warrants that R&R has as well.

[haysaw]

I'm sure that many far-more-informed-than-I individuals can answer this better, but I believe 'yes.' There is a precedent that shows Ampakines' efficacy in ADHD (CX717 obviously), and the therapeutic effects of Ampakines can be blanketed across the [LI] platform. It is true of RD anyway, and has been suggested by many of the experts to be the case in other indications as well.

[food4thought]

"Discovery Labs and FDA to Meet On September 29, 2009 to Discuss Potential Path for SURFAXIN Approval(GlobeNewswire)"

Cor might have been a bit more aggressive in this regard rather than spending all their money and focus on new less lucrative and defined indications. If the artifact issue was indeed as trivial as Stoll made it sound, they should have revisited clinical trials for adhd. Stock price would have held up better knowing a high revenue fda approval was still a possibility. Oh yeah, the letter. I'm sure it said piss off, so they did. Seems like the right move, for who would want to have the fda holding a grudge for a company soon to be tits up. Genius!